• Booth: 1218

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio includes bedside systems that enable monitoring of a patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solution is designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs.The company's shares are listed on Nasdaq First North (ticker SEZI).